Artificial Oxygen Carriers as Red Blood Cell Substitutes: A Selected Review and Current Status
- 20 August 2004
- journal article
- review article
- Published by Wiley in Artificial Organs
- Vol. 28 (9) , 813-828
- https://doi.org/10.1111/j.1525-1594.2004.07345.x
Abstract
Two distinct approaches are being explored in red blood cell substitute (RCS) development: hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon-based oxygen carriers (PFBOCs). HBOCs are based on intra- and/or intermolecularly "engineered" human or animal hemoglobins (Hbs), optimized for O2 delivery and longer intravascular circulation. Some are currently being evaluated in Phase II/III clinical studies. PFBOCs are aqueous emulsions of perfluorocarbon derivatives that dissolve relatively large amounts of O2. A PFBOC based on a 60% (wt/vol) emulsion of perfluorooctyl bromide has been evaluated in Phase II/III clinical trials. Although current PFBOC products generally require patients to breathe O2 enriched air, they render certain advantages since they are totally synthetic. This article provides a short review of the basic principles, approaches, and current status of RCS development. Results of preclinical and clinical studies including recent Phase II/III clinical studies are discussed.Keywords
This publication has 74 references indexed in Scilit:
- Hemolink™, an o‐raffinose cross‐linked haemoglobin‐based oxygen carrier, does not affect activation and function of human platelets in whole blood in vitroBritish Journal of Haematology, 2003
- Transfusion medicine: looking to the futurePublished by Elsevier ,2003
- Complement Activation and Thromboxane Secretion by Liposome-Encapsulated Hemoglobin in Rats in Vivo: Inhibition by Soluble Complement Receptor Type 1Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, 1997
- Influence of Perflubron Emulsion Particle Size on Blood Half-Life and Febrile Response in RatsArtificial Cells, Blood Substitutes, and Immobilization Biotechnology, 1994
- Development of Highly Fluid, Concentrated and Stable Fluorocarbon Emulsions for Diagnosis and TherapyBiomaterials, Artificial Cells and Immobilization Biotechnology, 1992
- Does intracoronary infusion of fluosol-DA 20% prevent left ventricular diastolic dysfunction during coronary balloon angioplasty?Journal of the American College of Cardiology, 1990
- Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol®The American Journal of Cardiology, 1990
- Fluosol-DA as a Red-Cell Substitute in Acute AnemiaNew England Journal of Medicine, 1986
- Encapsulation of hemoglobin in phospholipid vesiclesFEBS Letters, 1983
- On the use of ringer‐locke solutions containing hemoglobin as a substitute for normal blood in mammalsJournal of Cellular and Comparative Physiology, 1934